Thai Cannabis: From 2022 Decriminalisation to 2025 Recriminalisation and the Industry Whiplash
Thailand became Asia's first cannabis-decriminalising jurisdiction June 2022, sparked ~6,000 dispensaries and ~USD 1.5-2B grey-market industry. November 2024 Public Health Ministry rescheduled cannabis flower to controlled-narcotic; 2025 enforcement materially constrained recreational use. Medical-tier persists. Industry whiplash: hundreds of dispensaries closing 2025-2026, retail pivot to wellness/CBD, structural watch on policy oscillation.
Key takeaways
- 1
Thailand became Asia's first cannabis-decriminalising jurisdiction June 2022.
- 2
- 3
November 2024 Public Health Ministry rescheduled cannabis flower to controlled-narcotic.
- 4
2025-2026 enforcement materially constrained recreational use; medical-tier persists.
- 5
Hundreds of dispensaries closing 2025-2026; retail pivot to wellness/CBD.
- 6
Vertical-integrated operators (Rakanok, RCH8) structurally better positioned.
Questions this report answers
What's the Thai cannabis policy arc? Per Public Health Ministry directives: June 9 2022 decriminalisation under Anutin Charnvirakul (Bhumjaithai-led) β cannabis removed from Category 5 narcotic list, home cultivation, dispensary retail, food/beverage THC< allowed. November 2024 reschedule under Pheu Thai-led coalition β cannabis flower returned to controlled-narcotic, recreational use enforcement tightened 2025; medical-tier persists under prescription.[, ]
How big was the grey-market industry? Per Bangkok Post and Reuters: peak ~6,000 dispensaries 2024, ~ grey-market industry, tourist-driven Bangkok / Phuket / Chiang Mai concentration. Vertical-integrated operators (Rakanok, RCH8) anchored quality-tier; thousands of small dispensaries served price-tier.[]
What's the post-2024 industry whiplash? Per Bangkok Post: hundreds of dispensaries closing 2025-2026, retail pivot to wellness/CBD/lower-THC formulations, vertical-integrated operators structurally better positioned. GPO state-owned pharma runs medical-cannabis programme. Strategic read: Thai cannabis-policy oscillation is a Bhumjaithai-vs-Pheu-Thai political-coalition signal more than an economic one. Watch 2026-2027 directives, pre-2027-election cannabis-as-political-issue.[]
Executive summary
Thailand first Asian cannabis-decriminalising jurisdiction June 2022; peak ~6,000 dispensaries; ~ grey-market industry.[, ]
November 2024 Public Health Ministry rescheduled cannabis flower to controlled-narcotic. 2025-2026 enforcement constrained recreational use; medical-tier persists.[]
Industry whiplash: hundreds of dispensaries closing; retail pivot to wellness/CBD. Vertical-integrated operators better positioned. Watch 2026-2027 policy directives.[]
Thai cannabis policy arc
June 2022 decriminalisation
Value
Bhumjaithai-led
Notes
Asia's first; cannabis off Category 5 narcotic.
Peak dispensaries
Value
~6,000 (2024)
Notes
Bangkok / Phuket / Chiang Mai concentration.
Grey-market size
Value
Notes
Tourist-driven.
Nov 2024 reschedule
Value
Pheu Thai-led
Notes
Cannabis flower returned controlled-narcotic.
Post-2025 enforcement
Value
Recreational constrained
Notes
Medical-tier persists; hundreds dispensaries closing.
Medical-cannabis programme
Value
GPO state-owned pharma
Notes
Prescription-based dispensing.
| Metric | Value | Notes |
|---|---|---|
| June 2022 decriminalisation | Bhumjaithai-led | Asia's first; cannabis off Category 5 narcotic. |
| Peak dispensaries | ~6,000 (2024) | Bangkok / Phuket / Chiang Mai concentration. |
| Grey-market size | ~USD 1.5-2B | Tourist-driven. |
| Nov 2024 reschedule | Pheu Thai-led | Cannabis flower returned controlled-narcotic. |
| Post-2025 enforcement | Recreational constrained | Medical-tier persists; hundreds dispensaries closing. |
| Medical-cannabis programme | GPO state-owned pharma | Prescription-based dispensing. |
Dispensary licence attrition trajectory
Peak 2024
Active licences
18,433
Notes
Pre-recriminalisation high-water mark.
Jun 2025 (recriminalisation)
Active licences
~16,000
Notes
Medical-only rule takes effect.
Feb 2026
Active licences
11,136
Notes
7,297 closed; failed to renew under new rules.
2026 expiry wave
Active licences
~6,500 est.
Notes
4,587 additional licences expire 2026.
2027 est.
Active licences
~3,000
Notes
5,210 licences expire 2027; surviving medical-tier.
| Period | Active licences | Notes |
|---|---|---|
| Peak 2024 | 18,433 | Pre-recriminalisation high-water mark. |
| Jun 2025 (recriminalisation) | ~16,000 | Medical-only rule takes effect. |
| Feb 2026 | 11,136 | 7,297 closed; failed to renew under new rules. |
| 2026 expiry wave | ~6,500 est. | 4,587 additional licences expire 2026. |
| 2027 est. | ~3,000 | 5,210 licences expire 2027; surviving medical-tier. |
Analyst framing
Why this report matters
Unlock the full report
Need more than the web report? Ask for a scoped export or source appendix.
Every report keeps visible citations and source metadata. Terms.
Related reports
Thailand Cannabis & Hemp Industry Market Intelligence
Thailand became the first Asian country to decriminalise cannabis in June 2022, then reversed course in June 2025 when the Ministry of Public Health reclassified cannabis flower as a controlled herb under the Thai Traditional Medicine Knowledge Act. Prescriptions are now required, ~7,300 of 18,433 dispensaries closed by February 2026, and the draft Cannabis & Hemp Act remains pending in parliament. Hemp and CBD <0.2% THC continue as a separate cosmetic, food, wellness stream with export potential. Report maps the licensed operator base, listed exposure (RBF, KWM, ECF adjacents), ONCB enforcement coordination, hemp industrial value chain, and base, bull, bear scenarios anchored on Cannabis & Hemp Act passage timing.
Open report β
Thailand 2027 Election Outlook: People's Party and Pheu Thai Cycle
Thailand's political cycle since 2023 election: Move Forward (Pita Limjaroenrat) won plurality (151 seats) but court-disqualification, military-aligned-senate veto blocked government formation; Pheu Thai (Srettha Thavisin then Paetongtarn Shinawatra) formed coalition with conservative parties. Move Forward dissolved by Constitutional Court August 2024 over lese-majeste reform agenda; successor People's Party (Thee Pak Pravachoth) launched immediately, retained MPs. Thaksin Shinawatra returned from exile August 2023, served reduced sentence, paroled 2024. Thaksin pardon, lese-majeste cases (Section 112 Criminal Code) plus military-reform debates plus constitutional-amendment proposals shape political-cycle narrative. 2027 election outlook (constitutional cycle): Pheu Thai (incumbent) vs People's Party (largest opposition) plus military-aligned coalition (Bhumjaithai, Palang Pracharath, United Thai Nation). Senate composition shifted June 2024 (200-member elected senate, lower military influence). Investor-relevant policy fault lines: lese-majeste reform, military restructuring, foreign-investment policy continuity (BOI), tax reform (VAT 7β10%, Land-and-Building Tax). The structural-investor read: 2027 election outcome materially shifts policy continuity; Pheu Thai victory implies BOI, LTR continuity; People's Party victory implies more reformist agenda; coalition uncertainty highest.
Open report β
Thai Aging 65+ Trajectory and Fertility Collapse: Economic Impact
Thailand crossed the 'aged society' threshold (>14% of population aged 65+) in 2022 and is projected to enter 'super-aged' (>20%) by 2032-2034 β fastest demographic transition globally outside Japan and South Korea. 2024 estimates: 13M aged 65+ (~19% of population). Total fertility rate (TFR) collapsed to ~1.0 in 2024 (NSO Thailand) β among the lowest in Asia, below replacement (2.1), below Japan (1.36) and South Korea (0.78). Working-age population (15-64) peaked 2014; now declining ~0.5%/year. Old-age dependency ratio (OADR) ~28 in 2024, projected 50+ by 2040. Structural impact: healthcare-demand surge (sister report on aging-pensions-private-healthcare); pension-system strain (NSO, Social Security Office plus private provident funds; sister report on pension-provident-fund); CLMV migrant-labour reliance growing; automation adoption accelerating; consumer-segment shift (silver economy, age-care, retirement housing); fiscal trajectory deteriorating. Foreign LTR, retirement-visa pathways targeting silver-economy attraction. Watch TFR trajectory (any rebound to 1.2-1.3 would materially shift forecast), 65+ healthcare-spending trajectory, and pension-system reform.
Open report β
Thailand AI Drug Discovery & Pharma-Biotech 2027 Market Intelligence
Thailand's pharma sector is pivoting from Big Pharma agency, GPO generics, and bulk-API import toward AI-driven drug discovery, repurposing, biomarker stratification, and Thai-population-specific compound screening, propelled by the Genome Thailand 50K WGS cohort, the USD 35M BIOTEC AI Drug Discovery Centre, BOI Section 8 R&D tax incentives, and a TFDA accelerated approval pathway for AI-discovered compounds. By 2027 the addressable Thai AI drug discovery and pharma biotech AI-tooling pool reaches THB 14-24B revenue (vs THB 1.4-2.4B 2024). The report maps activity mix, operator concentration across BIOTEC, Mahidol, Chula, Siriraj, GPO, Siam Bioscience, Bionet-Asia, and the Insilico, Atomwise, Exscientia, Iktos Thailand JVs, plus unit economics, regulation, and 2031 scenarios.
Open report β